Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
about
Recent advances in treatment of acute coronary syndromesAntiplatelet drug interactions with proton pump inhibitorsSouthern Saskatchewan Ticagrelor Registry experience.Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients.Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelorIntravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy: A Systematic Review and Meta-analysis of 19 Studies.Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes.The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.Antiplatelets in acute coronary syndrome: personal perspectives.Ticagrelor: the first novel reversible P2Y(12) inhibitor.Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.Ticagrelor for acute coronary syndromes.New antithrombotics for secondary prevention of acute coronary syndrome.Outcomes of patients with prior coronary artery bypass graft who present with acute coronary syndrome.Significance of antiplatelet therapy in emergency myocardial infarction treatment.Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease.Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence.Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI.Antiplatelet strategies for secondary prevention of stroke and TIA.Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.Novel antiplatelet agents in acute coronary syndrome.Ticagrelor: a review of its use in adults with acute coronary syndromes.Antiplatelet treatment in essential hypertension: where do we stand?P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis.Anti-platelet therapy in small animal medicine.Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program.CHA2DS2-VASc risk factors as predictors of stroke after acute coronary syndrome: A systematic review and meta-analysis.Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease.Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.New antiplatelet agents prescribed to patients with ischemic heart disease: implications for treatment of stroke.One-year and longer dual antiplatelet therapy after an acute coronary syndrome: a Belgian position paper.[Focused update on dual antiplatelet treatment : ESC guidelines 2017].Clopidogrel Resistance in Neurovascular Stenting: Correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate.
P2860
Q26862897-C5748858-9A5B-4912-A66A-FD3E114C498DQ33948811-895A5DE4-D632-4E96-BDE0-B2355F019A99Q34387201-ECD6A716-6E43-41D9-9A55-0B3E024FB83CQ35111496-4A766B6F-5F4A-4F10-9BD7-150D53A5ED40Q35802189-1365BCBE-F697-4C31-A6C9-866247C15777Q36807413-28857B2B-1A3C-4328-910C-DB3713A8F906Q36956762-11E36AEC-A2ED-4F1D-87B4-B3F0C93A97AAQ37403998-BFCBD031-A94A-4BCB-BA85-929244DCFAA8Q38053481-4F348A08-3380-4097-8E1C-B79DB8E6CCBEQ38068595-D62E9F45-1B23-4699-AD8A-8A6E420FA916Q38069896-A511BEA5-4EFF-4716-A84A-4917988A4B41Q38151563-02874D96-822B-4278-9A69-DFB28DBBC0E5Q38154611-F7FC0384-30BD-40AC-BEA1-7D2355441FE3Q38180991-742DFE4F-9019-4031-8A49-9CFD6C42DF8DQ38206244-CDB7A93E-7255-414D-B09C-933651840317Q38209661-583678F3-4B35-41FA-A8B9-078ED185795AQ38213705-16524BA4-D3E1-4736-A4D4-177D5882C3E0Q38216499-4B0238B7-ECEB-402E-9D7D-A6887C655F21Q38243032-4A6814C3-E50A-4E43-89AA-E79FBDB82932Q38247544-7180478E-028D-40BD-85F2-55DBFE3B1549Q38254245-8AACB4E3-8972-4A28-BA8E-471E5434A43EQ38257119-77568D6A-11FA-45E6-9B0F-6A04106F3B9DQ38352069-E4141446-28DD-43BF-8419-D57172AFA674Q38384163-CD04E16E-087F-45E5-95DF-A3C103846BABQ38420789-BE00651B-49D0-4BAF-8FFD-7DC6BBA55AD9Q38545163-4E286CD2-63C2-4EC9-ADA9-B1DFAD611EFCQ38770733-8298A11D-0F7B-4368-9FC6-E368F5425C1CQ38869502-69CFE4AE-F338-4771-A9AD-3D004F677B6AQ38973172-C88C3AAA-5F1F-4425-A3F8-8260D1A52A17Q39093174-15F05081-59BF-422A-8908-51D5FDE253E9Q41060485-BAAB60B5-E925-48A6-8B6C-E09302B03CB3Q43955576-50AEBB8F-A791-4D8B-A380-E054F5D69408Q49088428-485C5614-93FB-4AC3-A0F7-B7F6FD5E79EDQ50085963-98AB82AE-2C6B-48E6-9026-97016D93A404Q50867606-4D0164CB-E1E5-4E71-9B0B-B744FC7FC441
P2860
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Ticagrelor versus clopidogrel ...... or transient ischemic attack.
@en
type
label
Ticagrelor versus clopidogrel ...... or transient ischemic attack.
@en
prefLabel
Ticagrelor versus clopidogrel ...... or transient ischemic attack.
@en
P2093
P1433
P1476
Ticagrelor versus clopidogrel ...... e or transient ischemic attack
@en
P2093
Dimitar Raev
Jose C Nicolau
Jose L Lopez-Sendon
Kenneth W Mahaffey
Matyas Keltai
Nardev S Khurmi
PLATO Study Group
Renato D Lopes
P304
P356
10.1161/CIRCULATIONAHA.111.082727
P407
P577
2012-05-09T00:00:00Z